M&A Deal Summary

Mallinckrodt Acquires Stratatech

On August 10, 2016, Mallinckrodt acquired life science company Stratatech

Acquisition Highlights
  • This is Mallinckrodt’s 5th transaction in the Life Science sector.
  • This is Mallinckrodt’s 8th transaction in the United States.
  • This is Mallinckrodt’s 1st transaction in Wisconsin.

M&A Deal Summary
Date 2016-08-10
Target Stratatech
Sector Life Science
Buyer(s) Mallinckrodt
Deal Type Add-on Acquisition

Target

Stratatech

Madison, Wisconsin, United States
Stratatech Corp. is a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Mallinckrodt

Dublin, United Kingdom
Category Company
Founded 1867
Sector Life Science
Employees2,673
Revenue 2.2B USD (2021)
DESCRIPTION

Mallinckrodt is a specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. Mallinckrodt was founded in 1867 and is based in Dublin, Ireland.

DEAL STATS #
Overall 8 of 12
Sector (Life Science) 5 of 9
Type (Add-on Acquisition) 7 of 10
State (Wisconsin) 1 of 1
Country (United States) 8 of 11
Year (2016) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-18 Medicines Company - Hemostasis Products

United States

Medicines Company - Hemostasis Products are RECOTHROM Thrombin topical (Recombinant), PreveLeak, and RAPLIXA (fibrin sealant) products used for blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques.

Buy $175M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-24 Mallinckrodt - Nuclear Imaging Business

Dublin, Ireland

Mallinckrodt - Nuclear Imaging Business includes a portfolio of diagnostic imaging products. Nuclear Imaging business originate in the U.S. The business is a prominent global producer of the key medical isotope molybdenum-99, from which technetium-99m (Tc-99m) is derived. Tc-99m is used in roughly 80%1 of all nuclear medicine procedures worldwide.

Sell $690M
Mergr

Product

Company

Legal